S SoftMaxx AI
Peptides · Evidence-graded entry

Acetyl tetrapeptide-3 and Capixyl claims: what the evidence shows

Acetyl tetrapeptide-3, evidence-graded: one randomized, triple-blind trial of a blend. Citations checked against PubMed and regulator records.

Written by SoftMaxx AI editorial · Citations checked against PubMed and regulator records · Updated 2026-10-03 · Not medically reviewed · How we grade evidence

SoftMaxx AI sells no peptides and takes no vendor money.

The verdict · strongest evidence Human RCT

Human RCT One randomized, triple-blind trial (32 people, 24 weeks) compared a blend of biochanin A, acetyl tetrapeptide-3 and ginseng with 3% minoxidil and found similar gains in terminal hair counts (8.3% vs 8.7%, no significant difference). It had no placebo arm, tested a multi-ingredient blend against 3% rather than 5% minoxidil, and its authors call for larger, longer studies.[1]

What Acetyl tetrapeptide-3 is

The EU cosmetic-ingredient database (CosIng) describes acetyl tetrapeptide-3 as 'Acetyl Tetrapeptide-3 is product obtained by the acetylation of Tetrapeptide-3', with the function 'skin protecting' [2]. The one human trial we found tested it inside a blend with biochanin A and ginseng extracts [1]. A 2025 review lists Capixyl among the most hyped topical hair actives [3]; none of the abstracts we read lists Capixyl's ingredients.

Claims vs. evidence

Each popular claim, graded by the strongest study behind it. The words in quotation marks are how the claim is marketed; the text after the grade is what the studies show.

Common myths, checked

Doses used in studies (not a recommendation)

Each row comes from the cited source: a study dose, a safety-review limit or a registered trial's planned dose, as labelled. Where the abstract states no amount, the row says so. They are a record of what was reported, not dosing instructions, and nothing here says what you should take.

Studied inRouteAmount reportedHow oftenHow longnSource
Humanstopical scalp solution (blend)1 mL of herbal extract combination (biochanin A, acetyl tetrapeptide-3, ginseng); peptide % not stated in abstract Study dosetwice daily24 weeks32[1] 32 men and women with mild–moderate androgenetic alopecia

Side effects and risks

Regulatory status (checked 2026-10-01 to 2026-10-03)

Report a side effect

If something went wrong after using a health product, tell a clinician. Report side effects to:

Common questions

Capixyl vs minoxidil which is better?

Human RCT The one trial we found compared a blend of biochanin A, acetyl tetrapeptide-3 and ginseng with 3% minoxidil, not 5%, in 32 people, and its authors call for larger, longer studies. A 2025 network meta-analysis confirms the efficacy of minoxidil, finasteride and dutasteride for male pattern hair loss.[1][5][6]

Does capixyl block DHT?

No supporting study We found no human study that measured DHT. The one human trial we found, of a blend containing acetyl tetrapeptide-3, reports hair counts and photographic assessment; its abstract does not report a DHT measurement.[1]

Acetyl tetrapeptide-3 vs minoxidil?

Human RCT One 32-person trial of a blend containing acetyl tetrapeptide-3 found results similar to 3% minoxidil, with no placebo arm, and its authors call for larger, longer studies. A 2025 network meta-analysis of 24 trials confirms the efficacy of topical and oral minoxidil for male pattern hair loss.[1][6][5]

Is capixyl safe?

Human RCT No local adverse reactions reported with the blend (vs one case of scalp eczema with 3% minoxidil).[1]

References

References to papers were matched to their PubMed or DOI records. Regulator, label and registry pages were fetched and saved by us; each status line under Regulatory status gives the date its source was captured. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.

  1. An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial. J Clin Aesthet Dermatol (2020). PubMed 33584955
  2. EU CosIng ingredient record: ACETYL TETRAPEPTIDE-3 EU CosIng (2026). Source
  3. Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology (2025). PubMed 40654553 DOI
  4. Overview of Short Peptides for Hair Loss. Biomedicines (2026). PubMed 42072405 DOI
  5. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol (2022). PubMed 35107565 DOI
  6. Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study. J Cosmet Dermatol (2025). PubMed 41051009 DOI

Written by SoftMaxx AI editorial · Citations checked against PubMed and regulator records · Updated 2026-10-03 · Not medically reviewed. Editorial standards · Evidence grading and update log.

Keep reading